Printer Friendly

LECTEC TO LAUNCH NEW PRODUCT FOR TREATMENT OF BED SORES AND OTHER CHRONIC WOUNDS

 LECTEC TO LAUNCH NEW PRODUCT FOR TREATMENT OF BED SORES
 AND OTHER CHRONIC WOUNDS
 MINNETONKA, Minn., May 28 /PRNewswire/ -- LecTec Corporation (NASDAQ: LECT) today announced plans to introduce a novel product to treat various pressure sores and other types of chronic wounds. The product, a highly absorptive gel-like material that adapts into any shape of wound or cavity, is expected to go to clinical trials this summer and be introduced to the market within one year.
 Business researchers project a potential market exceeding $1.5 billion by 1996 for pressure relief and wound care products. In the United States, an estimated 1.5 to 4 million people are afflicted with chronic, slow-healing wounds of the type that could be treated with the new product. Nearly 60,000 deaths in the United States occur each year as a result of complications from these chronic conditions.
 The LecTec product for chronic wounds, bed and pressure sores, includes a self-contained pliable package that maintains the pour-in- place material in a sterile condition. The material possesses unique and highly desirable conforming characteristics allowing the product to adopt the shape of the wound. Its absorptive and moisturizing properties are well-suited for treatment of bed sores, decubitus ulcers and other types of chronic pressure sores. In addition, the cohesive strength of the product allows it to be removed as a single unit during dressing changes with little or no residue. LecTec researchers have filed for a patent on the product which is now pending.
 The company announced that several marketing companies have expressed strong interest in the product. "We are seeking strategic marketing partners to effectively and efficiently deliver this product around the world," noted Robert Leick, director of sales and marketing for LecTec's Therapeutic Products Group. "The initial response to the concept is very encouraging."
 LecTec Corporation is a medical products company that manufactures and markets a variety of diagnostic and monitoring electrodes, medical tapes and transdermal drug delivery systems. The company is traded on NASDAQ under the symbol LECT.
 -0- 5/28/92
 /CONTACT: Jan Jachimowicz of LecTec, 612-933-2291/
 (LECT) CO: LecTec Corporation ST: Minnesota IN: MTC SU: PDT


KH -- MN007 -- 4628 05/28/92 10:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 28, 1992
Words:364
Previous Article:FIRST USA TO ISSUE 4.5 MILLION COMMON SHARES IN INITIAL PUBLIC OFFERING
Next Article:SUMMERTIME SIGNALS BEGINNING OF FAMILY GATHERINGS; MCI OFFERS FREE BROCHURE FOR ORGANIZING FAMILY REUNIONS
Topics:


Related Articles
LECTEC BOARD APPROVES ADDED EMPHASIS ON TRANSDERMAL BUSINESS DEVELOPMENT; CITES SIGNIFICANT OPPORTUNITIES
LECTEC REVIEWING POSSIBLE PATENT INFRINGEMENTS OF TRANSDERMAL NICOTINE TECHNOLOGY
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
LECTEC BOARD INTENSIFIES FUNDING FOR TRANSDERMAL PATCH DEVELOPMENT; TO TREAT SMOKERS, CANCER PATIENTS, OTHERS
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES APPROVAL OF COLLAGENASE SANTYL IN CANADA
BIOSPECIFICS TECHNOLOGIES CORP. LICENSEE RECEIVES MARKETING APPROVAL OF COLLAGENASE OINTMENT IN INDIA
BIOSPECIFICS TECHNOLOGIES CORP. COMMENTS ON FEDERAL GOVERNMENT HEALTH AGENCY'S REVIEW OF COLLAGENASE TREATMENT FOR PRESSURE ULCERS
ONCOGENE SCIENCE, INC. REPORTS INITIATION OF PHASE IB/II EUROPEAN CLINICAL TRIALS FOR WOUND HEALING
ONCOGENE SCIENCE, INC. ANNOUNCES INITIATION OF CLINICAL TRIALS IN THE UNITED STATES WITH TGF-BETA 3 FOR WOUND HEALING
PROCYTE LAUNCHES IAMIN(R) HYDRATING GEL

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters